Shares of Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $9.25 and traded as high as $10.49. Emergent BioSolutions shares last traded at $10.10, with a volume of 665,056 shares trading hands.
Analyst Upgrades and Downgrades
EBS has been the subject of several recent research reports. StockNews.com lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Friday, January 24th. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Finally, Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, November 7th.
Check Out Our Latest Stock Report on EBS
Emergent BioSolutions Stock Up 2.1 %
The firm's 50-day moving average price is $9.69 and its 200 day moving average price is $9.17. The firm has a market cap of $525.28 million, a P/E ratio of -2.36 and a beta of 1.62. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.
Hedge Funds Weigh In On Emergent BioSolutions
Several institutional investors have recently modified their holdings of EBS. SeaCrest Wealth Management LLC grew its position in shares of Emergent BioSolutions by 3.2% during the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company's stock worth $991,000 after acquiring an additional 3,705 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company's stock worth $6,192,000 after acquiring an additional 316,700 shares during the last quarter. PFG Investments LLC bought a new position in shares of Emergent BioSolutions during the third quarter worth about $228,000. Entropy Technologies LP bought a new position in shares of Emergent BioSolutions during the third quarter worth about $155,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Emergent BioSolutions in the third quarter worth about $141,000. Institutional investors own 78.40% of the company's stock.
Emergent BioSolutions Company Profile
(
Get Free Report)
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
Recommended Stories
Before you consider Emergent BioSolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.
While Emergent BioSolutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
